Characterisation, cytotoxicity and apoptosis studies of methotrexate-loaded PLGA and PLGA-PEG nanoparticles

Journal of Microencapsulation

Volumn 31, Issue 3, 2014, Pages 239-245

  Afshari, Majid ^a   Derakhshandeh, Katayoun ^a   Hosseinzadeh, Leila ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Cytotoxicity; Methotrexate; Nanoparticles

Indexed keywords

CASPASE 3; MACROGOL; METHOTREXATE; NANOPARTICLE; POLYGLACTIN; ANTINEOPLASTIC ANTIMETABOLITE; CASP3 PROTEIN, HUMAN; CYTOTOXIN; LACTIC ACID; MACROGOL DERIVATIVE; NANOCAPSULE; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYME ACTIVITY; IC 50; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CYTOTOXINS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTIC ACID; METHOTREXATE; NANOCAPSULES; NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; POLYGLYCOLIC ACID;

EID: 84909986361     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.834991     Document Type: Article

References (32)

1. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev, 2002;54:631-51.
2. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. 2001. Antineoplastic agents. In: Hardmann JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, pp. 1399-404.
3. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy- Nissenbauma E, Radovic-Morenob AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007;28:869-76.
4. Dadashzadeh S, Derakhshandeh K, HoseiniShirazi F. 9-Nitrocamptothecin polymeric nanoparticles: Cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anti-Cancer Drugs, 2008;19: 805-11.
5. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm, 2010; 67(3):217-23.
6. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9- nitrocamptothecin, a novelanticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm, 2007;66:34-41.
7. Derakhshandeh K, Soheili M, Dadashzadeh S, Saghiri R. Preparation and in vitro characterization of 9-nitrocamptothecin loaded long circulating nanoparticles for delivery in cancer patients. Int J Nanomedicine, 2010; 5:1-59.
8. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine: NBM, 2010;6:478-85.
9. Ebrahimnejad P, Dinarvand R, Jafari MR, SajadiTabasi SA, Atyabi F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int J Pharm, 2011;406:122-7.
10. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int J Pharm, 2008;349:249-55.
11. Fernandez-Carballoido A, Pastoriza P, Barica E, Montejo C, Negro S. PLGA/PEG derivative polymeric matrix for drug delivery system application: Characterization and cell viability studies. Int J Pharm, 2008;352:50-7.
12. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanism of action of methotrexate. Immuno Pharmacol, 2000;47: 247-57.
13. Harsh V, Bharat G, Vishnu A. Preparation and physicochemical characterization of methoteraxtae PLGA microparticles. Int J Pharm Res, 2010;2(1):75-81.
14. Holdenrieder S, Stiebe P. Apoptotic markers in cancer. Clin Biochem, 2004;37:605-17.
15. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release, 2007;118:7-17.
16. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to SandimmuneNeoral. J Control Release, 2007;119:197-206.
17. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)- folate conjugate. Langmuir, 2005;21:8852-7.
18. Kosasih A, Bowman BJ, Wigent RJ, Ofner III CM. Characterization and in vitro release of methotrexate from gelatin: Methotrexate conjugates formed using different preparation variables. Int J Pharm, 2000;204: 81-9.
19. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces, 2010;75: 1-18.
20. Mazur A, Nowak D, Mannherz HG, Malicka-B?aszkiewicz M. Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton. Eur J Pharmacol, 2009; 613:24-33.
21. Mashima T, Naito M, Tsuruo T. Caspase-mediated cleavage of cytoskeletal actin plays appositive role in the process of morphological apoptosis. Oncogene, 1999;18:2423-30.
22. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia KH, Ehyaei N, Valizadeh H. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B: Biointerfaces, 2011;88: 39-44.
23. Müller RH. 1991. Charge determinations. In: Müller RH, ed. Colloidal carriers for controlled drug delivery and targeting modification, characterization and in vivo distribution. Boca Raton, FL: CRCPress, pp. 57-97.
24. Ofner CM, Pica K, Bowman BJ, Chen CS. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates. Int J Pharm, 2006;308:90-9.
25. Padmanabhan S, Tripathi DN, Vikram A, Ramarao P, Jena GB. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: Intervention of folic and folinic acid. Mutat Res, 2009;673: 43-52.
26. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: NBM, 2009;5:410-18.
27. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res, 2000;45:528-37.
28. Seo DH, Jeong YI, Kim DG, Jang MJ, Jang MK, Nah JW. Methotrexateincorporated polymeric nanoparticles of methoxy poly (ethylene glycol)-grafted chitosan. Colloids Surf B: Biointerfaces, 2009;69: 157-63.
29. Singh R, Lillard Jr JW,. Nanoparticle-based targeted drug delivery. Experiment Mol Pathol, 2009;86:215-23.
30. Taheri A, Atyabi F, Salman Nouri F, Ahadi F, Derakhshan MA, Amini M, Ghahremani H, Ostad SN, Mansoori P, Dinarvand R. Nanoparticles of conjugated methotrexate-human serum albumin: Preparation and cytotoxicity evaluations. J Nanomaterials, 2011; 2011:1-7.
31. Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxy xanthone. Eur J Pharm Biopharm, 2005;59: 491-500.
32. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metastasis Rev, 1992;11: 95-103.